Cancer of the prostate. Mechanisms of action of antiandrogens
Habenicht, U.F.; Neumann, F.; el Etreby, M.F.
Acta Urologica Belgica 59(4): 1-10
1991
ISSN/ISBN: 0001-7183 PMID: 1840231 Document Number: 379182
Document emailed within 1 workday
Related Documents
Pavone-Macaluso, M.; Serretta, V.; Pavone, C.; Romano, C.; Daricello, G. 1989: Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate Archivos Espanoles de Urologia 42(Suppl 2): 197-205He, Y.; Liu, Y.-g.; Cen, S.; Zhou, J.-m. 2015: The mechanisms of drug resistance in prostate cancer Yao Xue Xue Bao 50(7): 797-801
Youle, R J. 2003: Haya Lorberboum-Galski and Philip Lazarovici (Eds.). Chimeric Toxins: Mechanisms of Action and Therapeutic Applications (Cell and Molecular Mechanisms of Toxin Action) International Journal of Toxicology 22(4): 331-332
Naito, S.; Shiota, M. 2014: The concept and mechanisms of castration-resistant prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 72(12): 2090-2094
Roznovanu, S.L.ăc.ăm.; Amălinci, C.; Rădulescu, D.ţa. 2005: Molecular mechanisms in hormone-resistant prostate cancer Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 109(3): 577-583
Komiya, A.; Yasuda, K.; Watanabe, A.; Fuse, H. 2011: Basic mechanisms of androgen-independent growth in the prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 96-103
Sander, S. 1999: Monotherapy with antiandrogens for prostatic cancer Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 119(10): 1451-1453
McKee, J.M. 1994: Cues to action in prostate cancer screening Oncology Nursing Forum 21(7): 1171-1176
Koga, H.; Yamaguchi, A.; Miyazaki, Y.; Naito, S. 2011: Action assignment of mass screening for prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 5): 217-220
Rhim, J.S. 2003: Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro prostate cell models Drugs of Today 39(11): 837-847
Troll, W.; Frenkel, K.; Wiesner, R. 1987: Protease inhibitors: possible preventive agents of various types of cancer and their mechanisms of action Progress in Clinical and Biological Research 239: 297-315
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319